JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
245 produits trouvés pour "JAK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
XL019
CAS :<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formule :C25H28N6O2Degré de pureté :99.19%Couleur et forme :SolidMasse moléculaire :444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS :<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formule :C16H13Cl2N3O2Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :350.2Cerdulatinib
CAS :<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Formule :C20H27N7O3SDegré de pureté :98.74% - 99.49%Couleur et forme :SolidMasse moléculaire :445.54Protosappanin A
CAS :<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Formule :C15H12O5Degré de pureté :99.42% - 99.82%Couleur et forme :SolidMasse moléculaire :272.25AMG-47a
CAS :<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formule :C29H28F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :535.56Decernotinib
CAS :<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formule :C18H19F3N6ODegré de pureté :99.28% - >99.99%Couleur et forme :SolidMasse moléculaire :392.38G5-7
CAS :<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formule :C22H19F2NO3Degré de pureté :97.3%Couleur et forme :SolidMasse moléculaire :383.39(E/Z)-Zotiraciclib
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formule :C23H24N4ODegré de pureté :97.75% - 99.92%Couleur et forme :SolidMasse moléculaire :372.46FLLL32
CAS :<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formule :C28H32O6Degré de pureté :97% - 97.90%Couleur et forme :SolidMasse moléculaire :464.55AG490
CAS :<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formule :C17H14N2O3Degré de pureté :98.6% - 99.39%Couleur et forme :Yellow SolidMasse moléculaire :294.3GDC-0214
CAS :<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formule :C28H28ClF2N9O3Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :612.03Baricitinib
CAS :<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formule :C16H17N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :371.42Peficitinib
CAS :<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formule :C18H22N4O2Degré de pureté :98.67% - 99.4%Couleur et forme :SolidMasse moléculaire :326.39Pyridone 6
CAS :<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formule :C18H16FN3ODegré de pureté :97.1% - 98.74%Couleur et forme :SolidMasse moléculaire :309.34WHI-P97
CAS :<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Formule :C16H13Br2N3O3Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :455.1JANEX-1
CAS :<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Formule :C16H15N3O3Degré de pureté :98% - 99.81%Couleur et forme :SolidMasse moléculaire :297.31WP1066
CAS :<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formule :C17H14BrN3ODegré de pureté :98.92% - 99.73%Couleur et forme :SolidMasse moléculaire :356.22Fedratinib hydrochloride hydrate
CAS :<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formule :C27H40Cl2N6O4SDegré de pureté :98.96% - 99.87%Couleur et forme :SolidMasse moléculaire :615.61AZ960
CAS :<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formule :C18H16F2N6Degré de pureté :96.02% - 98.51%Couleur et forme :SolidMasse moléculaire :354.36ZM39923 hydrochloride
CAS :<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Formule :C23H25NO·HClDegré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :367.91BMS-911543
CAS :<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Formule :C23H28N8ODegré de pureté :97.69% - 99.98%Couleur et forme :SolidMasse moléculaire :432.52SAR-20347
CAS :<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formule :C21H18ClFN4O4Degré de pureté :98.99% - 99.77%Couleur et forme :SolidMasse moléculaire :444.84FM-381
CAS :<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formule :C24H24N6O2Degré de pureté :98.44%Couleur et forme :SolidMasse moléculaire :428.49TG101209
CAS :<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formule :C26H35N7O2SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :509.67Deucravacitinib
CAS :<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formule :C20H19D3N8O3Degré de pureté :98.52% - >99.99%Couleur et forme :SolidMasse moléculaire :425.46RO495
CAS :<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formule :C17H14Cl2N6ODegré de pureté :97.94%Couleur et forme :SolidMasse moléculaire :389.24SC99
CAS :<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formule :C15H8Cl2FN3ODegré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :336.15Brevilin A
CAS :<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formule :C20H26O5Degré de pureté :99.97% - >99.99%Couleur et forme :SolidMasse moléculaire :346.42Cerdulatinib hydrochloride
CAS :<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Formule :C20H28ClN7O3SDegré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :482GS-829845
CAS :<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Formule :C17H19N5O2SDegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :357.43NVP-BSK805
CAS :<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Formule :C27H28F2N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :490.55Solrikitug
CAS :<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Degré de pureté :95%Couleur et forme :LiquidZM39923
CAS :<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Formule :C23H25NODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :331.45(3S,4S)-Tofacitinib
CAS :<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37SD-1029
CAS :<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Formule :C25H32Br2Cl2N2O3Couleur et forme :SolidMasse moléculaire :639.25JAK-IN-11
CAS :<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Formule :C23H22FN5O4SDegré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :483.52JAK-IN-20
CAS :<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formule :C28H30FN7O2Couleur et forme :SolidMasse moléculaire :515.58JAK-2/3-IN-2
CAS :<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formule :C19H19ClN2OSCouleur et forme :SolidMasse moléculaire :358.89Peficitinib hydrochloride
CAS :<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formule :C18H23ClN4O2Couleur et forme :SolidMasse moléculaire :362.86TK4b
CAS :<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formule :C21H22N2O2Couleur et forme :SolidMasse moléculaire :334.41TK4g
CAS :<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formule :C19H19N3O4SCouleur et forme :SolidMasse moléculaire :385.44JAK-IN-14
CAS :<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formule :C19H15FN4ODegré de pureté :98.27%Couleur et forme :SolidMasse moléculaire :334.35TyK2-IN-2
CAS :<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formule :C16H18N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :310.35JAK-IN-18
CAS :<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formule :C27H28F2N6O3Couleur et forme :SolidMasse moléculaire :522.55JAK3-IN-12
CAS :<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formule :C19H19N5O4SCouleur et forme :SolidMasse moléculaire :413.45Tyk2-IN-5
CAS :<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formule :C21H19FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :434.43EP009
CAS :<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formule :C14H24O2Couleur et forme :SolidMasse moléculaire :224.34Tyk2-IN-7
CAS :<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formule :C18H15D3N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.46MS-1020
CAS :<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formule :C21H18N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :346.381,2,3,4,5,6-Hexabromocyclohexane
CAS :<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formule :C6H6Br6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :557.54
